New COVID-19 vaccine shows promise in large trial
NCT ID NCT05212948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested a new COVID-19 vaccine called S-268019-b in nearly 10,000 adults. Participants received either the vaccine or a placebo to see if it could prevent COVID-19. The study looked at how many people got sick after vaccination and checked for safety and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- S-268019-b vaccine
- What this could lead to
- If successful, this vaccine could help prevent COVID-19, reducing infections and severe illness.
- What could go wrong
- This trial is completed, but results may not apply to new variants. As with any vaccine, there is a small risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Buon Ma Thuot City Medical Center
Buon Ma Thuot, Dak Lak, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Millions of vaccine records scoured for rare side effects
- Scientists probe why lung disease raises COVID-19 risk
- New rapid test could spot COVID and flu in minutes
- New saliva test could diagnose COVID-19 in under an hour